[go: up one dir, main page]

CU24621B1 - Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 - Google Patents

Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5

Info

Publication number
CU24621B1
CU24621B1 CU2020000051A CU20200051A CU24621B1 CU 24621 B1 CU24621 B1 CU 24621B1 CU 2020000051 A CU2020000051 A CU 2020000051A CU 20200051 A CU20200051 A CU 20200051A CU 24621 B1 CU24621 B1 CU 24621B1
Authority
CU
Cuba
Prior art keywords
bicyclic heterocyclic
substituted bicyclic
prmt5 inhibitors
heterocyclic components
formula
Prior art date
Application number
CU2020000051A
Other languages
English (en)
Other versions
CU20200051A7 (es
Inventor
Balasaheb Gore
Ganesh Gudade
Anil Hajare
Rajender Kamboj
Chaitanya Kulkarni
Sanjeev Kulkarni
Dipak Lagad
Prathap Nair
Venkata Palle
Chetan Pawar
Sachin Sethi
Milind Sindkhedkar
Mahadeo Tryambake
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CU20200051A7 publication Critical patent/CU20200051A7/es
Publication of CU24621B1 publication Critical patent/CU24621B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<p>La invención se refiere a compuestos heterocíclicos bicíclicos sustituidos de fórmula (I),</p> <p>ESPACIO PARA FÓRMULA (I)</p> <p>a sales de clorhidrato de los mismos y a composiciones farmacéuticas que comprenden al menos un compuesto de fórmula (I).</p>
CU2020000051A 2017-12-13 2018-12-13 Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 CU24621B1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201721044886 2017-12-13
IN201821024634 2018-07-02
IN201821040029 2018-10-23
PCT/IB2018/060015 WO2019116302A1 (en) 2017-12-13 2018-12-13 Substituted bicyclic heterocyclic compounds as prmt5 inhibitors

Publications (2)

Publication Number Publication Date
CU20200051A7 CU20200051A7 (es) 2021-03-11
CU24621B1 true CU24621B1 (es) 2022-09-08

Family

ID=65036860

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000051A CU24621B1 (es) 2017-12-13 2018-12-13 Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5

Country Status (29)

Country Link
US (2) US11459330B2 (es)
EP (1) EP3724190B1 (es)
JP (1) JP7282778B2 (es)
KR (1) KR102708147B1 (es)
CN (1) CN111712498B (es)
AU (1) AU2018385664B2 (es)
BR (1) BR112020011746A2 (es)
CA (1) CA3085259A1 (es)
CL (1) CL2020001576A1 (es)
CR (1) CR20200263A (es)
CU (1) CU24621B1 (es)
DK (1) DK3724190T3 (es)
ES (1) ES2927860T3 (es)
GE (1) GEP20227359B (es)
HR (1) HRP20221207T1 (es)
HU (1) HUE059945T2 (es)
IL (1) IL274936B2 (es)
LT (1) LT3724190T (es)
MX (1) MX2020006181A (es)
PE (1) PE20211444A1 (es)
PH (1) PH12020550881A1 (es)
PL (1) PL3724190T3 (es)
PT (1) PT3724190T (es)
RS (1) RS63623B1 (es)
SG (1) SG11202004934QA (es)
SM (1) SMT202200396T1 (es)
UA (1) UA126349C2 (es)
WO (1) WO2019116302A1 (es)
ZA (1) ZA202003528B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
JOP20210060A1 (ar) 2018-10-05 2023-01-30 Vertex Pharma معدلات لمضاد تريبسين ألفا-1
KR20210145787A (ko) 2019-04-02 2021-12-02 알리고스 테라퓨틱스 인코포레이티드 Prmt5를 표적으로 하는 화합물
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CN114126614A (zh) * 2019-05-30 2022-03-01 安杰斯制药公司 作为prmt5抑制剂的杂环化合物
PT3980417T (pt) * 2019-06-10 2023-12-28 Lupin Ltd Inibidores de prmt5
WO2021079302A1 (en) 2019-10-22 2021-04-29 Lupin Limited Pharmaceutical combination of prmt5 inhibitors
JP2022553376A (ja) * 2019-10-25 2022-12-22 アクセント・セラピューティクス・インコーポレイテッド Ｍｅｔｔｌ３モジュレーター
AU2020394887A1 (en) * 2019-12-03 2022-06-16 Lupin Limited Substituted nucleoside analogs as PRMT5 inhibitors
WO2021202480A1 (en) * 2020-04-01 2021-10-07 Aligos Therapeutics, Inc. Compounds targeting prmt5
US20230159504A1 (en) * 2020-04-03 2023-05-25 Vertex Pharmaceuticals Incorporated 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd)
EP4188920A1 (en) 2020-07-31 2023-06-07 Tango Therapeutics, Inc. Piperidin-1-yl-n-pyrydine-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers
JP2024502886A (ja) 2021-01-19 2024-01-23 ルピン・リミテッド がんを処置及び／又は予防するためのｓｏｓ１阻害薬の医薬組合せ
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009574A1 (en) 2002-07-22 2004-01-29 Novartis Ag Synthesis of discodermolide
WO2005016878A2 (en) 2003-08-13 2005-02-24 Isis Pharmaceuticals, Inc. METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
WO2007141473A1 (en) 2006-06-09 2007-12-13 Astrazeneca Ab N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
SG10201506608RA (en) 2008-09-26 2015-09-29 Agency Science Tech & Res 3-deazaneplanocin derivatives
US9044432B2 (en) 2009-12-22 2015-06-02 Ohio State Innovation Foundation Compositions and methods for cancer detection and treatment
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
AU2011272198B2 (en) 2010-06-30 2016-09-22 Fujifilm Corporation Novel nicotinamide derivatives or salts thereof
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
ES2608053T3 (es) 2011-08-19 2017-04-05 Glaxosmithkline Intellectual Property (No. 2) Limited Inhibidores de ácido graso sintasa
CA2869954C (en) * 2012-04-20 2023-01-03 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity
WO2013185103A1 (en) 2012-06-08 2013-12-12 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
WO2014008223A2 (en) 2012-07-03 2014-01-09 Glaxosmithkline Llc Fatty acid synthase inhibitors
RS58040B1 (sr) 2012-12-21 2019-02-28 Epizyme Inc Prmt5 inhibitori i njihove upotrebe
WO2014100716A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9221794B2 (en) 2012-12-21 2015-12-29 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
CA2942833A1 (en) 2013-03-15 2014-09-18 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
JP6559123B2 (ja) 2013-10-10 2019-08-14 アラクセス ファーマ エルエルシー Ｋｒａｓｇ１２ｃの阻害剤
KR101898364B1 (ko) 2014-05-22 2018-09-12 에프. 호프만-라 로슈 아게 인돌린-2-온 및 1,3-다이하이드로-피롤로[3,2-c]피리딘-2-온 유도체
MA40219B1 (fr) 2014-06-25 2021-08-31 Glaxosmithkline Ip Dev Ltd Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
EP3160477A4 (en) 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20170210751A1 (en) 2014-06-25 2017-07-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CA2953572A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
EP3189048B1 (en) 2014-09-03 2021-03-17 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
EP3189041B1 (en) 2014-09-03 2021-04-28 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
EP3191592A1 (en) 2014-09-11 2017-07-19 Novartis AG Inhibition of prmt5 to treat mtap-deficiency-related diseases
SG11201706050WA (en) 2015-02-24 2017-09-28 Pfizer Substituted nucleoside derivatives useful as anticancer agents
WO2016145150A2 (en) 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI791251B (zh) * 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
EP3377481A1 (en) 2015-11-16 2018-09-26 Araxes Pharma LLC 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2018065365A1 (en) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors

Also Published As

Publication number Publication date
LT3724190T (lt) 2022-10-10
EP3724190A1 (en) 2020-10-21
KR20200098598A (ko) 2020-08-20
WO2019116302A1 (en) 2019-06-20
US20220267339A1 (en) 2022-08-25
PL3724190T3 (pl) 2022-10-31
AU2018385664B2 (en) 2022-06-02
PE20211444A1 (es) 2021-08-05
DK3724190T3 (da) 2022-10-10
PH12020550881A1 (en) 2021-04-05
HUE059945T2 (hu) 2023-01-28
ES2927860T3 (es) 2022-11-11
CN111712498B (zh) 2023-09-29
EP3724190B1 (en) 2022-07-06
KR102708147B1 (ko) 2024-09-19
SMT202200396T1 (it) 2022-11-18
CR20200263A (es) 2020-07-26
CU20200051A7 (es) 2021-03-11
US11952380B2 (en) 2024-04-09
GEP20227359B (en) 2022-03-10
IL274936A (en) 2020-07-30
AU2018385664A1 (en) 2020-07-02
IL274936B1 (en) 2023-05-01
HRP20221207T1 (hr) 2022-12-09
JP2021506793A (ja) 2021-02-22
JP7282778B2 (ja) 2023-05-29
UA126349C2 (uk) 2022-09-21
SG11202004934QA (en) 2020-07-29
BR112020011746A2 (pt) 2020-11-17
RS63623B1 (sr) 2022-10-31
US20210163486A1 (en) 2021-06-03
ZA202003528B (en) 2022-05-25
US11459330B2 (en) 2022-10-04
IL274936B2 (en) 2023-09-01
CA3085259A1 (en) 2019-06-20
MX2020006181A (es) 2020-09-03
CL2020001576A1 (es) 2020-11-06
CN111712498A (zh) 2020-09-25
PT3724190T (pt) 2022-10-03

Similar Documents

Publication Publication Date Title
CU24621B1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
CU20210009A7 (es) Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3)
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
CY1125359T1 (el) Νεα υποκατεστημενα με 6-6 δικυκλικο αρωματικο δακτυλιο νουκλεοσιδικα αναλογα για χρηση ως αναστολεις prmt5
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CU20180019A7 (es) Derivados de heteroarilo como inhibidores de parp
DK3704120T3 (da) Heterocykliske forbindelser som prmt5-inhibitorer
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CR20150045A (es) Inhibidores de hepatitis c
SV2016005137A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
UY35300A (es) Formulación de combinación de dos compuestos antivirales
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
BR112019025028A2 (pt) Método para preparar um composto.
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
CO2022001860A2 (es) Derivados quinolina como inhibidores de proteína quinasa
DOP2016000312A (es) Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2